Agendia, a Boston, MA-based molecular cancer diagnostics company, has raised USD$65m in equity financing.
The round was led by the Debiopharm Group, with participation from current investors The Van Herk Group, ING Corporate Investments, Breedinvest and Gilde Healthcare, as well as new backers Korys and others.
The company intends to use the funding to expand commercialization of its recently launched breast cancer Symphony suite of tests, as well as development of its personalized medicine pipeline. Agendia is preparing to launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction.
Led by CEO David Macdonald, Agendia develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Its breast cancer Symphony™ suite includes MammaPrint, an FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, an alternative therapy selection assay.